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Introduction
Chronic rhinosinusitis (CRS) in adults is defined as a sino-
nasal inflammation persisting for > 12 weeks characterized
by nasal obstruction/congestion/blockage, nasal drainage
(mucopurulent), facial pain/pressure/fullness, and decreased
or loss of sense of smell.1,2 It is a highly prevalent condition,
affecting  12 to 15.2% of the adult population in the United
States, exceeding other common respiratory conditions such
as acute asthma or chronic bronchitis.2 It has a direct impact
on the overall quality of life andwell-being of the patient,3 as
well as on the health care system; the overall direct cost
burden of CRS in the United States has been estimated at US$
8.6 billion per year.4
Surgery for CRS is generally indicated when symptoms
persist despite medical therapy. Functional endoscopic









► drug delivery systems
Abstract Introduction Chronic rhinosinusitis (CRS) is a highly prevalent pathology in our
society. Due to the prevalence of this condition and to the persisting symptoms despite
an appropriate medical treatment, surgical techniques are often required. Lately,
minimal invasive techniques have been described, such as lacrimal diversion devices
(LDDs). This technique offers a fast and convenient choice for delivery of sinus irrigation
and topical medication.
Objective We aimed to describe our experience with LDDs and evaluate the safety
and effectiveness of the procedure in patients with moderate to severe CRS without
nasal polyposis (CRSsNP) and persistent symptomatology despite medical therapy.
Methods A total of 7 patients underwent bilateral lacrimal stents placement in the
operating room. A retrospective observational study was conducted. The Sino-Nasal
Outcome Test-20 (SNOT-20) survey was performed and the score obtained was
compared before and 1 month after the procedure.
Results The LDDs were used for an average of 80 days. During the follow-up, only three
patients had amild complicationwith the device (granuloma in the punctum, obstruction,
and early extrusion). The mean baseline SNOT-20 score dropped significantly (p ¼ 0.015)
from 25.85 to 11.57 (mean: - 14.29) 1 month after the procedure.
Conclusion According to our experience and results, the use of LDD is a novel,
feasible, and less invasive technique to treat refractory CRS. It reduces the risk of
mucosal stripping, provides short-term outcomes, and the surgical procedure does not
require advanced training in endoscopic sinus surgery. Moreover, it can be performed
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98.4% of the patients at 7.8 years of follow-up.5 The
efficacy of FESS can be attributable to the restoration of
the ventilation and to the drainage of the paranasal
sinuses by enlarging the narrowed or obstructed sinus
ostia, and also by improving the topical delivery of med-
ications to the sinonasal mucosa.6 Surgical techniques
have evolved from open approaches to endoscopic ones,
and, lately, minimal invasive tissue-sparing techniques
have been described.
Minimally invasive techniques have been categorized as
minimally invasive sinus technique (MIST), which include all
procedures directed at the spaces around the sinus ostia
avoiding the sinus ostia, such as the ethmoid punch sinu-
sotomy (EPS),7,8 and the balloon catheter dilatation (BCD)
sinusotomy, which directly dilate the natural ostia of the
large sinuses—the maxillary, frontal and sphenoid. The ante-
rior and posterior ethmoid sinuses cannot be directly
addressed with BCD.8
The used of lacrimal diversion devices (LDDs) is a novel
and alternative technique for the delivery of sinus irrigation
of the anterior ethmoid-frontal recess area. The LDD stent is
a flexible polymeric conduit designed to maintain a patent
lumen between the lateral aspect of the caruncle and the
paranasal sinus via an osteotomy in the lacrimal bone. (The
Sinopsys Lacrimal Stent [Synopsys Surgical, Inc., Boulder,
CO, USA] is currently an investigational device in the United
States for sinus irrigation and is commercially available in
the European Union under the CE Mark) This procedure
allows the sinus irrigation and topical delivery of medica-
tion via a transcaruncular-ethmoid sinus route. A cadaver
study has shown that delivering irrigation to the anterior
ethmoid region is a feasible technique that can be used as a
potential alternate technique for the delivery of sinus
irrigation.9
The objective of the present study is to describe our
experience with LDDs and to evaluate the safety and effec-
tiveness of the procedure in patients with CRSwithout nasal
polyposis (CRSsNP). All of the patients were previously
treated with medical therapy without a complete response
to the treatment and were candidates for procedural
intervention.
Materials and Methods
After providing informed consent, 7 patients (> 18 years old)
with moderate to severe CRSsNP who had persistent symp-
toms despite medical therapy (1 course of oral antibiotics,
9-day taper of oral corticoids, 3months of topical fluticasone
and saline nasal irrigations) underwent bilateral lacrimal
stent placement in the operating room. A standard sinus
computed tomography (CT) was previously performed to
evaluate to disease and to determine the location and the
approximate trajectory for the placement of the LDD.
Patients underwent planned turbinoplasty, septoplasty, or
additional sinus procedures as deemed required. The
patients were discharged with a cycle of 10 days of ophthal-
mic drops of corticosteroids / antibiotics alternated with
saline drops.
Surgical Procedure
The placement of LDDs was performed following the recom-
mendations of the manufacturer. The insertion is performed
in a supine position. An eyelid retractor and a corneal
protector are placed first, then a 25G needle is inserted in
the region of the caruncle, and a local anesthetic is infiltrated
(lidocaine hydrochloride and epinephrine).Afterwards, a
21G x 1-inch needle mounted on a 5-ml saline-filled syringe
is inserted behind and inferiorly to the caruncle, and the
needle is advanced in a lateral to medial and caudal trajec-
tory to encounter the bony junction between the medial
orbit and the lacrimal fossa just anterior to the superior
aspect of the posterior lacrimal crest. It passes between the
superior and inferior canaliculi and posterior and superior to
the common canaliculus. The needle is advanced through the
lacrimal bone perpendicular to the surface of the bone;
aspiration and observation of air flash in the syringe con-
firms the placement. A guidewire is placed through the
needle lumen using the Seldinger technique (►Fig. 1). The
21G needle is removed and the obturator with cannula is
inserted; subsequently, the obturator is removed and a
trephine is inserted to enlarge the osteotomy (►Fig. 2).
Finally, the lacrimal stent delivery instrument is advanced
over the guidewire into proper placement. The guidewire
and sheath are then removed.
Statistical Analysis and Outcome Measures
A retrospective observational study of patients who under-
went LDD placement in our center was performed. To assess
the impact and tomeasure the outcome of the technique, the
Sino-Nasal Outcome Test-20 (SNOT-20) survey was per-
formed before and 1 month after the procedure. The student
t-test was used to compare variables, and p < 0.05 was
considered statistically significant.
Results
A total of 7 patients who underwent LDD placement where
included (3 females, 4males), with amean age of 52.71 years
old. The average preprocedure SNOT-20 score was 25.85
(►Table 1). In all of the patients, the procedure was per-
formed under general anesthesia, and the LDDs were cor-
rectly placed without any complications during the surgery.
All of the patients required an additional intervention: 71%
underwent concomitant septoplasty, 14% a turbinoplasty,
and 85% required a concomitant sinus procedure (sinus
osteotomy or balloon sinuplasty)
The average time the LDDs were used was 80 days (range:
6–124 days) (►Table 1). In the follow-up, one patient had a
device-related mild complication, a granuloma in the punc-
tum that was self-limited; in one patient the stents suffered
from an obstruction and were therefore removed; and one
patient had an early extrusion of the stents (►Table 2).
The SNOT-20 scores at baseline and at 1 month after the
surgery for all patients are shown in ►Fig. 3. The reduction
observed in the score was clinically and statistically signifi-
cant (p ¼ 0.015), with a mean reduction of -14.29 (standard
deviation [SD]: 11.25) (►Table 1).
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Fig. 1 Using the Seldinger technique, place the guidewire through
and down the lumen of the needle. Apply gentle finger pressure on the
guidewire to maintain position in the anterior ethmoid or in the nasal
cavity while removing the needle.
Fig. 2 While maintaining the placement of the guidewire, remove the
trephine with a gently reversed twisting motion and then remove the
cannula.






1 14 3 11
2 24 2 22
3 17 8 9
4 14 8 6
5 77 45 32
6 28 7 21








Abbreviations: SD, standard deviation.









6 61 Granuloma (punctum)
7 6 Extrusion
Mean (SD) 80 (45.82)
Abbreviations: LDD, lacrimal diversion device; SD, standard deviation.
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Discussion
Nowadays, FESS is considered a highly effective technique
when addressing medically refractory CRS.10 Nevertheless,
different efforts to develop minimally invasive techniques to
achieve the same goals of increased sinus ventilation,
improved topical drug delivery and avoidance of mucosal
damage have been developed.8
Our experience and results suggest that the placement of
LDDs for patients with CRSsNP is an achievable and safe
intervention. The learning curve of this procedure is rela-
tively fast, and adequate placement was achieved in all
patients. We found a clinically and statistically significant
improvement 1 month after surgery in the SNOT-20 score of
all patients. Although most of our patients used the stent
for > 1 month, the score was only assessed in all of them
1 month after the surgery, and the following revisions dif-
fered significatively in time in all of them, and not all of them
were reassessed with the questionnaire; for this reason, we
could only evaluate them objectively in this single period of
time. However the ideal duration for stents and drug-eluting
stents in sinus surgery has not been defined.11 Most inves-
tigators recommend the use of stents for at least 6weeks, but
there have been some authors who describe prolonged
stenting for years.12,13
A previous cadaver study had proven that LDDs can be
used as a potential alternate technique for the delivery of
sinus irrigation.9 To our knowledge, there are not any studies
published yet in the literature describing the outcomes of
this technique in patients, although Nayak et al, in a poster
session presented at the Combined Otolaryngology Spring
Meeting in April 2018,14 described 23 patients with symp-
toms of sinusitis/CRS who received bilateral LDDs under
conscious sedation in 2 different institutions. The SNOT-20
score declined significantly at day 7 and at day 30 in one
institution, and at week 4 and at week 8 in the other
institution. The Lund-Mackay radiographic score was also
assessed in this last group, also presenting a significant
improvement. The author has also described some locore-
gional complications, including foreign body sensation, pre-
septal inflammation, and device occlusion in a minority of
cases that were self-limited.
Minimally invasive techniques can be categorized asMISTs,
such as Ethmoid punch sinusotomy and balloon catheter
dilatation (BCD) sinusotomy.7,8 We understand that LDDs
could be considered as a MIST. This technique can improve
topical irrigation and re-establish the nasal ventilation in
patients with CRS with ethmoid sinus compromise, where
topical nasal treatment has limited penetration. Furthermore,
it can be considered as a less invasive rhinologic procedure for
the treatment of ethmoid sinusitis. It also has advantages over
FESS, such as a lower risk of mucosal stripping, which may
result in sinus bone exposure and, eventually, in scarring and
in the recrudescenceof theCRS disease.15 It can also be rapidly
performed when compared with FESS, does not require
advanced training in endoscopic sinus surgery, and can be
performed in-office under local anesthesia or sedation. Mini-
mally invasive techniques had demonstrated short-term out-
comes comparablewithFESS,16but theevidenceof supporting
the use of these techniques is limited and longer outcomes
remain controversial.17
The main limitation of the present study is that the
outcome of LDD placement and, therefore, the reduction in
the SNOT-20 score cannot be fully separated from the effects
of an additional turbinoplasty, septoplasty, or another sinus
procedure performed in the patients. Long-term outcomes
need to be assessed, and studies in larger populations with
comparative groups might provide a better support for this
new technique.
Conclusion
The use of LDDs (Sinopsys Lacrimal Stent) is a novel and
feasible technique that is part of this new wave of less
invasive rhinologic procedures for the treatment of CRS
that do not respond to medical treatment. It can also be
considered a less invasive alternative for the treatment of the
ethmoid sinus, which is frequently involved with inflamma-
tory disease and exacerbations of the symptoms. This novel
approach can be performed in-office with minimal disrup-
tion of the local mucosa, and improve topical irrigation and
medication of the ethmoid sinus.
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